Exactech Innovations Simplify the Complexity of Revision Total Joint Replacement
March 01 2016 - 9:00AM
Business Wire
Exactech Unveils New Knee, Hip and Shoulder
Revision Systems during AAOS 2016 Annual Meeting, Exhibit #3881
Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone
and joint restoration products for extremities, knee, hip, spine
and biologic solutions, announced today its lineup of products to
be unveiled at the company’s educational exhibit, Booth #3881, at
the American Academy of Orthopedic Surgeons (AAOS) 2016 Annual
Meeting, March 1-5 in Orlando, Fla.
“We have focused our recent development efforts on delivering
innovations that resolve some of the most complex and challenging
demands that orthopaedic surgeons face in the O.R. -- revision
total joint surgery,” said Exactech Chief Executive Officer David
Petty. “We are eager to launch three new revision implant and
instrumentation systems this year and to share updates to our
InterSpace® spacers, AcuDriver® cement removal systems and biologic
solutions, which fully equip surgeons to tackle whatever they face
when revising a total joint implant.”
Highlights of Exactech’s latest innovations for revision
arthroplasty include:
- The only modular device for reverse
shoulder arthroplasty with significant proximal bone loss, the
Equinoxe® Humeral Reconstruction Prosthesis offers a unique
and stable solution for complex and challenging humeral
reconstruction cases. *
- Exactech’s new comprehensive
Revision Knee System delivers a high-performance portfolio
of implants, instruments and advanced surgical technology for
reproducible results in a streamlined revision procedure.
- The Alteon® Monobloc Revision
Femoral Stem incorporates the functionality of a modular design
with the simplicity of a monobloc stem. A press-fit, distally
fixed, one-piece tapered, splined titanium stem, it is designed to
improve surgical experiences and clinical outcomes.
- The newest addition to the
InterSpace® family, the Tapered Wedge Hip Spacer, allows
surgeons to more conservatively treat patients following a
peri-prosthetic joint infection of a wedge-style hip stem. Exactech
is pleased to share the data behind InterSpace’s preformed spacer
technology with 20+ years’ clinical experience.
Also an important complement to revision surgery, Exactech
offers biologic solutions such as Optecure®, an engineered
bone graft for reconstruction of the spine, pelvis and extremities.
Optecure and Optecure+CCC can be used in complex cases to help
repair bone defects.
In addition to a renewed focus on revision total joint
arthroplasty, Exactech’s technical staff and surgeon consultants
will share their experiences with other recent market introductions
such as the Alteon® Tapered Wedge Femoral Stem and enhancements to
the Equinoxe® platform shoulder system. A focal point of Exactech’s
educational exhibit will be live demonstrations of ExactechGPS®
Guided Personalized Surgery system, a computer-assisted technology
which supports the Optetrak Logic® comprehensive primary knee
system.
Visit www.exac.com/academy for more information on featured
products, scheduled clinical experts and live demonstrations.
*The Equinoxe Humeral Reconstruction Prosthesis is not indicated
for use with the reverse shoulder components in oncology
applications.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160301006067/en/
Exactech, Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance & Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024